|
|
|
Please Note: Press Releases are in Adobe .pdf
format.
To view these documents requires the use
of Adobe
Acrobat Reader, available for free.
Tapestry Receives Notice Regarding Minimum Bid Price Rule
Boulder, Colo., December 21, 2007 – Tapestry Pharmaceuticals, Inc. (NASDAQ: TPPH) today announced that it received notice on December 18, 2007 from The Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore not in compliance with Marketplace Rule 4310(c)(4). In accordance with the Nasdaq Marketplace Rule 4310(c)(8)(D), Tapestry has until June 16, 2008, which is 180 calendar days from December 18, 2007, to regain compliance. This notification does not have immediate affect on the listing of the Company's common stock.
December 21, 2007
Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
Boulder, Colo., December 5, 2007 – Tapestry Pharmaceuticals, Inc. (NASDAQ: TPPH) today announced the appointment of Eric K. Rowinsky, M.D., and Martin Cannon to the Company’s Board of Directors. Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. Mr. Cannon is the President and Chief Executive Officer for New Health Sciences, Inc
December 5, 2007
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data from its Phase 2 Prostate Cancer Trial
[WEBCAST]
Boulder, Colo., November 5, 2007 – Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today financial results for the third quarter ended September 26, 2007.
November 5, 2007
Browse all press releases...
|
|
|
